A phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR)
Authors:
- C ErlichmanCEC Erlichman
- M MooreMMM Moore
- J ThiessenJTJ Thiessen
- C DeAngelisCDC DeAngelis
- P GoodmanPGP Goodman
- J ManzoJMJ Manzo
- 1 September 1994
- journal article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 5, 42